GSK超出盈利预期，提升了2025年的财报指引，并见证了强劲的机构采购。 GSK beat earnings estimates, raised 2025 guidance, and saw strong institutional buying.

GSK在10月29日报告Q3收入丰厚, 公布收入1.48 EPS和11.35B美元, GSK reported strong Q3 earnings on October 29, posting $1.48 EPS and $11.35B in revenue, surpassing estimates, with 6.7% year-over-year revenue growth. 该公司将其2025年EPS指南提高到4.73至4.81美元,并宣布季度股息为0.4171美元。 The company raised its 2025 EPS guidance to $4.73–4.81 and announced a $0.4171 quarterly dividend. 机构活动包括由第一银行和信托增加61.5%的股份,以及大量内部购买1.47M股。 Institutional activity included a 61.5% stake increase by First Bank & Trust and a major insider purchase of 1.47M shares. 股票上涨超过200天移动平均数,交易额为48.58美元,市场上限为99.07B美元,并维持一致的“稳住”评级。 The stock rose above its 200-day moving average, trading at $48.58 with a market cap of $99.07B, and maintains a consensus "Hold" rating.